Disease · MONDO_0001780

premature ejaculation

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. premature ejaculation. Diseases, record MONDO_0001780. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001780

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: premature ejaculation; Open Targets
Open Targets ID: MONDO_0001780; Open Targets
Other names: premature ejaculation (disease), rapid ejaculation; Open Targets
Disease Ontology: DOID:13709; Disease Ontology
MeSH: D061686; MeSH
NCI Thesaurus: C94349; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 29 drugs, from DailyMed; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LIDOCAINE	CHEMBL79	Small molecule	Approval	DailyMed	11	6	6	Drugs and targets
PRILOCAINE	CHEMBL1194	Small molecule	Approval	EMA Human Drugs, at withdrawal	3	2	2	Drugs and targets
BENZOCAINE	CHEMBL278172	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
MELUADRINE	CHEMBL2104709	Small molecule	Preapproval	TTD	1	0	0	Drugs and targets
DAPOXETINE	CHEMBL2110900	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
PAROXETINE	CHEMBL490	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
HYALURONIC ACID	CHEMBL5314376		Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
TADALAFIL	CHEMBL779	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
TRAMADOL HYDROCHLORIDE	CHEMBL1237065	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FOLIC ACID	CHEMBL1622	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets34

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A4	Sodium-dependent serotonin transporter	4	Serotonin transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	3	Adrenergic receptor alpha-1 antagonist; Alpha-1a adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2/3	https://conductscience.org/library/genes/6616	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	2	Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets
SCN10A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6326	Drugs and targets

1 to 10 of 34

See all 34 targets

Trials53

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01063855	Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction	Phase 3	495	2012-11-05	Erectile Dysfunction, Sexual Dysfunction	DAPOXETINE	Its record names the disease	ClinicalTrials.gov
NCT01063881	The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy	Phase 3	285	2012-10-31	Sexual Dysfunction, Physiological	DAPOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00556478	Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation	Phase 2/3	256	2016-09-26	Premature Ejaculation	LIDOCAINE, PRILOCAINE	Its record names the disease	ClinicalTrials.gov
NCT03055806	IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)	Phase 2	239	2019-10-07	Premature Ejaculation	CHEMBL594828	Its record names the disease	ClinicalTrials.gov
NCT02844998	The Impact and Benefit of Physical Activity on Premature Ejaculation	Not applicable	120	2017-09-29	Premature Ejaculation	DAPOXETINE	Its record names the disease	ClinicalTrials.gov
NCT02232425	IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)	Phase 2	88	2019-01-24	Premature Ejaculation	CHEMBL594828	Its record names the disease	ClinicalTrials.gov
NCT01021553	A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation	Phase 2	77	2017-09-12	Premature Ejaculation	EPELSIBAN	Its record names the disease	ClinicalTrials.gov
NCT01917006	A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation	Phase 2	59	2018-10-18	Premature Ejaculation	ONABOTULINUMTOXINA, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01021670	An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride		10,027		Sexual Dysfunction, Physiological, Ejaculation	DAPOXETINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01230762	An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation	Phase 3	1,774		Ejaculation, Erectile Dysfunction, Sexual Dysfunction	DAPOXETINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 53

See all 53 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PDE5I + PLACEBO vs PDE5I + DPX: serious adverse events	4 of 245	3 of 250	495	NCT01063855	Trial comparisons
Drug: IX-01 vs Placebo: Incidence of Treatment-emergent Adverse Events	12 of 56	9 of 30	86	NCT02232425	Trial comparisons
Drug: IX-01 vs Placebo: serious adverse events	0 of 56	0 of 30	86	NCT02232425	Trial comparisons

Papers from its trials17

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25356302	RESULT	1	PubMed
24883105	RESULT	1	PubMed
21256670	RESULT	1	PubMed
21059176	RESULT	6	PubMed
21050394	RESULT	1	PubMed
19195772	RESULT	1	PubMed
18498422	RESULT	1	PubMed
17352514	RESULT	1	PubMed
16962882	RESULT	2	PubMed
31351660	DERIVED	1	PubMed

1 to 10 of 17

See all 17 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001780

GET https://conductscience.org/api/diseases/v1/MONDO_0001780/drugs?page=2

API reference For AI assistants